MarginsXMarginsX
Home › Markets › Health Care › GRI

GRI Bio Inc. (GRI)

GRI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.40
-18.60% on the day
Market cap
$3.1M
Nano cap
Revenue · 2021
$0
-100.0% on 2020
Net income · 2021
-$9.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1824293/000182429322000004/0001824293-22-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.

Profile

FieldValue
TickerGRI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001824293
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2021

LineValue
Revenue$0
Net income-$9.3M
Operating income-$9.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$3.7M
Total assets$8.3M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
12.6 months
$10.9M cash at June 30, 2026
Share count, 1 year
+1772.6%
2025-11-13 to 2026-11-12 · +2916826.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Therefore, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements."
10-Q 2026-11-13
Cash and burn$10.9M cash; operating cash flow -$2.6M a quarter.Report 2026-06-30
Shares outstanding2,186,115 (2026-11-12); 3,268,727 a year earlier; 3,246,354 three years earlier. 1y figure adjusted for splits (1-for-28 overall); 3y figure adjusted for splits (1-for-43316 overall).Cover page 2026-11-12
Reverse splits, 3 years4; latest 1-for-28 on 2026-01-26Source 2026-01-26
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-01-30
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2025-12-02
AuditorWithumSmith+Brown, PC, San Francisco, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$1.6M-$1.4M$10.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$2.0M-$3.7M$11.0MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$2.7M-$3.0M$8.2MNo debt tagsNeeds four quarters10-K 2026-01-30
Q3 2025
2025-09-30
Not filed-$3.4M-$2.3M$4.1MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$2.9M-$3.2M$5.1MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$3.0M-$1.7M$3.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$1.9M-$2.0M$5.0MNo debt tagsNeeds four quarters10-K 2026-01-30
Q3 2024
2024-09-30
Not filed-$2.1M-$2.3M$4.7MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-01-30
Latest annual report10-K2026-01-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-04
Latest proxyDEF 14A2026-09-28

Source: SEC EDGAR submissions feed, 409 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.6%
1 month+9.7%
3 months-4.0%
Year to date-75.4%
1 year-96.4%
From 52-week high-97.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
RDHLRedhill Biopharma Ltd.$0.3605-3.87%$3.2M
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M
SILOSilo Pharma Inc.$1.57-14.40%$3.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier